A research team from Japan investigated expression of insulin-like growth factor-I receptor (IGF-IR) in pancreatic cancer cell lines. All the cell lines examined expressed IGF-IR under culture conditions without IGF-I in the medium. They suggest that IGF-IR and phosphatidylinositol 3 kinase are good candidates for molecular therapy of pancreatic cancer.
Insulin-like growth factor-I (IGF-I) is upregulated in human pancreatic cancer tissues but is not expressed in surrounding non-cancerous tissues. Serum level of IGF-I is elevated in pancreatic cancer patients. Histological analysis has shown that IGF-I receptor (IGF-IR) is positive in the membrane of pancreatic cancer tissues. These facts suggest that IGF-I acts as a growth factor for pancreatic cancer and inhibition of its action might be a good candidate for molecular therapy of pancreatic cancer. A possible problem is that not all pancreatic cancers produce IGF-I, which might be a reason for ineffective results of its clinical application.
A research team from Japan have proved that inhibition of IGF-IR activity results in a decrease in proliferation and motility of pancreatic cancer cell lines. Their study will be published on April 21, 2010 in the World Journal of Gastroenterology.
Their study indicated that IGF-IR was expressed and played a role in proliferation and motility of pancreatic cancer cell lines. Further analysis of this phenomenon could unveil a new role for a growth factor receptor and its downstream pathway in cancer. One possible mechanism would be that the downstream pathway stimulates its upstream receptor via some unknown molecule, like a retrograde flow.
Explore further: Team identifies source of most cases of invasive bladder cancer
More information: Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 2010; 16(15): 1854-1858. www.wjgnet.com/1007-9327/full/v16/i15/1854.htm